# Ziconotide: a new option for refractory pain.

> PubMed lists PMID 16845440 in Drugs of today (Barcelona, Spain : 1998) as Journal Article, Review, with publication-date metadata of 2006-06 (month precision). PeptideScanner associated the retained record with the identity slug ziconotide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-16845440-ziconotide:v1`
- Evidence domain: Literature metadata
- Date in source: 2017-04-27
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-13
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-16845440-ziconotide/
- JSON record: https://peptidescanner.com/evidence/v1/objects/pubmed-pmid-16845440-ziconotide-v1.json
- Content SHA-256: `86bc8d2b65f35a10fe3f805dafb3ba9fc0b2d24cd679a4183d4641853c0558ae`

## Claims and source pins

### Headline

Ziconotide: a new option for refractory pain. ([`pubmed-observation-pmid-16845440-2017-04-27-77de67ac0c43`](#source-pubmed-observation-pmid-16845440-2017-04-27-77de67ac0c43))

### Summary

PubMed lists PMID 16845440 in Drugs of today (Barcelona, Spain : 1998) as Journal Article, Review, with publication-date metadata of 2006-06 (month precision). PeptideScanner associated the retained record with the identity slug ziconotide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-16845440-2017-04-27-77de67ac0c43`](#source-pubmed-observation-pmid-16845440-2017-04-27-77de67ac0c43))

### Paragraph 1

PubMed lists PMID 16845440 in Drugs of today (Barcelona, Spain : 1998) as Journal Article, Review, with publication-date metadata of 2006-06 (month precision). PeptideScanner associated the retained record with the identity slug ziconotide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-16845440-2017-04-27-77de67ac0c43`](#source-pubmed-observation-pmid-16845440-2017-04-27-77de67ac0c43))

### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-16845440-2017-04-27-77de67ac0c43`](#source-pubmed-observation-pmid-16845440-2017-04-27-77de67ac0c43))

## Sources

<a id="source-pubmed-observation-pmid-16845440-2017-04-27-77de67ac0c43"></a>
- **Ziconotide: a new option for refractory pain. · retained source version 1:2017-04-27:current:77de67ac0c433595c9ffcb4d43d15e50bf2b946aa038705e5d7ee57af18b8639** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/16845440/) (`pubmed-observation-pmid-16845440-2017-04-27-77de67ac0c43`)

## Correction lineage

No correction is recorded for this version.

## Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

## Suggested citation

PeptideScanner. "Ziconotide: a new option for refractory pain." Version 1, published 2026-08-13. https://peptidescanner.com/evidence/v1/objects/pubmed-pmid-16845440-ziconotide-v1.json SHA-256: 86bc8d2b65f35a10fe3f805dafb3ba9fc0b2d24cd679a4183d4641853c0558ae.